Caberlin 0.25 mg (Cabergoline 0.25 mg)

Caberlin 0.25 mg (Cabergoline 0.25 mg)

Overview: Caberlin 0.25 mg contains Cabergoline, a dopamine receptor agonist used primarily to treat conditions caused by high levels of prolactin, a hormone produced by the pituitary gland. By lowering prolactin levels, it helps manage related health issues.

Uses:

1. Hyperprolactinemia: Caberlin 0.25 mg is prescribed to treat elevated prolactin levels, which can cause menstrual irregularities, infertility, and unwanted lactation in women, and can affect fertility and hormone levels in men.
2. Prolactinomas: Helps manage benign pituitary tumors that lead to overproduction of prolactin.
3. Parkinson’s Disease (off-label): Occasionally used in treating Parkinson’s symptoms due to its dopamine-stimulating effects.

Dosage:

• A typical starting dose is 0.25 mg twice a week, but the dosage may be adjusted based on how well the patient responds to the treatment. Always follow the doctor’s prescribed dose.

How to Take:

• Take Caberlin 0.25 mg with food to minimize stomach upset.
• Swallow the tablet whole with water; do not chew or crush it.

Possible Side Effects:

• Common side effects: Nausea, dizziness, headache, and fatigue.
• Serious side effects (rare): Chest pain, mood changes, shortness of breath, or swelling in the extremities. Contact your doctor if you experience any severe symptoms.

Precautions:

• Pregnancy and Breastfeeding: Use only under a doctor’s supervision during pregnancy, and avoid while breastfeeding as it suppresses milk production.
• Blood Pressure: Cabergoline can lower blood pressure; regular monitoring may be necessary, especially during the initial treatment period.

Interactions:

• Caberlin may interact with medications that affect dopamine or blood pressure. Always inform your doctor about any other medications or supplements you are taking.

Storage:

• Store in a cool, dry place, away from direct sunlight and out of reach of children.

Always follow your healthcare provider’s advice on dosage and usage.